Research programme: autoimmune, inflammatory and vascular disease therapeutics - Charite University/sanofi-aventis

Drug Profile

Research programme: autoimmune, inflammatory and vascular disease therapeutics - Charite University/sanofi-aventis

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Charite of Berlin; sanofi-aventis
  • Developer Charite of Berlin; Sanofi
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Inflammation; Stroke

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Stroke in Germany
  • 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Germany
  • 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top